MDMA works to ensure that FDA’s pre- and post-market efforts are predictable, transparent, and reasonable for medical technology innovators. Regulatory professionals work collaboratively through the FDA Working Group to develop priorities to communicate before FDA’s Center for Devices and Radiological Health (CDRH), Members of Congress, and other relevant stakeholders.